For the past three decades, collaborations, deals and best practice exchanges on innovation and commercialisation have been a ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of up to $250m.

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and ...

Eli Lil­ly is set to pay up to $415 million in an ALS deal with Alchemab Therapeutics ... A federal judge sided with the FDA over its decision last year to remove Lilly’s GLP-1 drug tirzepatide from ...

Patricia Clarkson plays the equal pay activist Lilly Ledbetter in this misty-eyed drama. By Beatrice Loayza When you purchase a ticket for an independently reviewed film through our site ...

Under the terms of the agreement, Alchemab will be taking the programme through early phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab’s ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – ATLX-1282 is the first programme out of ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aché, Alchemab, Bavarian, Biomea, Eli Lilly, Firstgene ...